Home › La Jolla Pharmaceutical Company Announces First Patient Enrolled In Clinical Trial Of LJPC-501 In Hepatorenal Syndrome
 

Keywords :   


La Jolla Pharmaceutical Company Announces First Patient Enrolled In Clinical Trial Of LJPC-501 In Hepatorenal Syndrome

2014-09-03 11:49:25| drugdiscoveryonline Home Page

La Jolla Pharmaceutical Company a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, recently announced that the first patient has been enrolled in the Phase 1/2 clinical trial of LJPC-501 for the treatment of type 1 and type 2 hepatorenal syndrome (HRS). HRS is a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure

Tags: company trial patient clinical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
10.05Argentines strike against spending cuts
10.05Two Daytona Waste Pro Drivers Jump into Action After Car Crash
10.05Together for Safer Roads and National Waste & Recycling Association Announce New Participants in FOCUS on Fleet Safety Training
10.05Start Your Day with Tom Gratz, Sales Manager USA, Hitachi Zosen Inova
10.05Scotlands Road to Circularity and Its Water Utilitys Sustainability Story
10.05Simplified Environmental Solutions (SES) Expands Zero Waste to Landfill Operations to Salt Lake City and Kansas City
10.05Zero Waste Lunch at WasteExpo Showcases Potential of Leftover, Undesirable Foods
10.05Rubicon Announces Sale of Fleet Technology Business Unit
More »